2025年生命科学领域进展指标：如何判断行业是否处在上升期

ResearchBrief

2025Indicatorsof

Progressforthe

LifeSciencesSector

HOWWILLWEKNOWIFTHESECTOR

ISADVANCINGIN2025?

JANUARY

2025

TableofContents·

Overview1

1.Greatertrustinlifesciencescompanies3

2.Reductioninout-of-pocketcostsforpatients5

3.Expandedpatientaccesstohealthcareservices7

4.Progressonthe“MakeAmericaHealthyAgain”agenda9

5.Morefocusondiseasepreventionandearlyintervention11

6.Restoredgrowthintheemergingbiopharmasector13

7.Improvementsinclinicaldevelopmentdecision-making,15

processesandtechnologydeployment

8.Expandeduseofnoveladvancedtherapies17

9.HigherFreshnessIndexforlifesciencescompanyproductportfolios19

10.IncreasedcontributionfrommarketsoutsideofU.S.21

toglobalsalesforlifesciencescompanies

References23

AbouttheInstitute26

REFERENCINGTHISREPORT

Pleaseusethisformatwhenreferencingcontentfromthisreport:

Source:IQVIAInstituteforHumanDataScience.ResearchBrief:2025IndicatorsofProgressfortheLifeSciencesSector:

Howwillweknowifthesectorisadvancingin2025?Availablefrom

©2025IQVIAanditsaffiliates.Allreproductionrights,quotations,broadcasting,publicationsreserved.Nopartofthispublicationmaybereproducedor

transmittedinanyformorbyanymeans,electronicormechanical,includingphotocopy,recording,oranyinformationstorageandretrievalsystem,withoutexpresswrittenconsentofIQVIAandtheIQVIAInstitute.

2025IndicatorsofProgressfortheLifeSciencesSector:Howwillweknowifthesectorisadvancingin2025?

Overview

Theyearaheadforthelifesciencessectorwillbedefinedbyadvancesinscience,researchanddevelopment,

marketplacedynamics,economics,andpolitics.There

willbesuccessesandchallengesalongtheway,andnoshortageofuncertainty.Thisresearchbriefoutlines

severalfactorsthatcanbeusedasindicatorsofpositiveprogressin2025forthelifesciencesindustryacross

multipledomains,includingindustryreputation,

researchandclinicaldevelopmentproductivity,biotechfunding,earlyintervention,therapeuticinnovation,

patientaccesstohealthcareservices,andhealthpolicy.Theseindicatorsarenotintendedaspredictionsofwhatwillhappen—butratheraseriesofexplicitmarkersthatwillreflectprogressiftheyareachievedbytheendof

theyear.

•Greatertrustinlifesciencescompanies:Alackofpublictrustinthepharmaceuticalindustryleadstodiminishedpoliticalsupportandcredibility,patienthesitancy,andlessuseofmedicines.Progresswillberecognizedifthepositivepublicviewofthe

pharmaceuticalindustryimprovesto25%in2025from20%lastyear.

•Reductioninout-of-pocketcostsforpatients:

Drugpricesareperceivedbythepublictobetoohighlargelythroughtheout-of-pocketcostsborneby

patientswithorwithoutinsurance,andareaflashpointforpolicymakers,leadingtofinger-pointingamong

stakeholdersanddrivingmisguidedpolicies.Progressin2025willbeachievedifaveragebrandprescriptionout-of-pocketcostsfallbelow$25andtheshareof

brandprescriptionscarryingpatientcostsofmorethan$125fallstolessthan3%ofthetotal.

•Expandedpatientaccesstohealthcareservices:

Fewerinteractionsbetweenpatientsandhealthcareprofessionalsresultinfeweropportunitiesfor

medicinestobeconsideredastreatmentoptions

andtheirfullvaluedeliveredtopatients.Forthelifesciencessector,progresscanbemarkedbyproxy

measuressuchasthestabilizationofthenumberofactivepharmaciesin2025(wherepharmacyclosuresinover-saturatedareasareoffsetbyopeningsin

pharmacydesertareas);anincreaseof2%inthe

numberofprimarycareactiveprescriberstomatchgrowthinthe65+population;andgrowthinnew

brandprescriptionsof4%,upfromthe1.5%growthin2024.

•Inclusiveprogressonthe“MakeAmerica

HealthyAgain”(MAHA)agenda:AsthenextU.S.

administrationbringsnewapproachesandprioritiestothehealthcaresector,thepotentialexistsforpolicyandregulatoryactionsthatbringuncertainty,delaysanddisruptionfortheindustry.Apositiveindicatorin2025willbeaninclusiveapproach—includingthelifesciencessector—todefiningandpursuingaMAHA

agendathatinvolvespublic/privatefundingfocusedonpreventionandunderstandingdiseaseetiology.

•Morefocusondiseasepreventionandearly

intervention:Thelifesciencessectorremainsheavilydependentondevelopingandcommercializing

treatmentsforlate-stagediseaseandsymptom

management.ConsistentwiththeMAHAagenda,

progressinplacingmorefocusandfundingfordiseasepreventionandearlyinterventionwillbeanimportantindicatorfortheindustry.Thiscouldincludeimprovingvaccinationratesforchildrentopre-pandemiclevels

wheremorethan20statesreportMMRvaccinationratesinexcessof95%;andincreasedspendingonprimarycareto6%oftotalhealthspendingin2025.

Therewillbesuccessesand

challengesalongtheway,andnoshortageofuncertainty.

|1

•Restoredgrowthintheemergingbiopharma

sector:Emergingbiopharmacompaniesrequirestablefundingsourcesandexitstrategies,bothofwhichhavebeenchallengingoverthepastthreeyears.Sincethesecompaniesrepresentabout60%ofclinicaltrialactivityglobally,theirstrengthandgrowtharevitaltothe

broadersector.In2025,ariseintheXBIBiotechIndexof20%andgrowthinthevalueofannouncedM&A

biopharmadealsto$200Bnwillbeimportantpositiveindicatorsforthispartoftheinnovationecosystem.

•Improvementsinclinicaldevelopmentdecision-making,processes,andtechnologydeployment:

Pharmaceuticalresearchanddevelopmentis

highlyriskyandPhaseIIprojectsuccessrateshavehoveredstubbornlyaround30%inrecentyearsat

thetotalindustrylevel—resultinginhigherclinicaldevelopmentcostsandmorethan13yearselapsingfrompatentfilingtopatientavailabilityofnew

medicines.Manyeffortstoimprovedecision-making,processes,andtechnologydeploymentmaybe

reflectedinanincreaseinaveragePhaseIIsuccessratesforindustry-sponsoredinterventionaltrialstomorethan35%in2025andwouldmarkapositiveinflectionpointforthesector.

•Expandeduseofnoveladvancedtherapies:

Thelifesciencessectorhasmadegreatprogress

inbringingthroughdevelopmentandregulatory

approval,andgrowinganumberofnovelcellandgenetherapiesandotheradvancedmodalities.However,

Achievingtheindicatedlevelsof

changewillreflectmeaningful

advancementforthesector—

andpositiveoutcomesforother

stakeholderswhorelyonlifesciencesfortheadvancementofhealthandwellnessforall.

thelimitedaccessanduseofthesetherapiesbringsuncertainsustainabilitytothisareaofinnovation.

Positiveindicatorsofprogressin2025wouldbethe

increaseduseofCART-celltherapies,forexample,inthirdlineorlatermultiplemyelomatomorethan8%oftreatmentregimensintheU.S.and5%inEU4+UK.Additionally,bringingapprovedsicklecellgene

therapiesapprovedin2023totreatjust2%ofeligiblepatientsbytheendoftheyearwouldreflectpositivelyonthesenoveladvancedtherapies.

•HigherFreshnessIndexforlifesciencescompany

productportfolios:Balancingthecycleofinvestmentininnovationwiththegenerationofreturnsduringadefinedperiodofexclusivityisahallmarkofsuccessfullifesciencescompanies.Inrecentyears,product

portfolioshavenotbeenfullyreplenishedatthe

rateneededtosustaininvestmentininnovation.An

indicatorofprogressin2025wouldbeanimprovementintheFreshnessIndexthatwouldtaketheshareof

brandeddrugsalesfromlaunchesinthepriorfiveyearsfrom20%to25%,andtheshareofsalesfromlaunchesinthepriordecadefrom60%to65%.

•Increasedcontributionfrommarketsoutsideof

theU.S.toglobalsalesoflifesciencescompanies:Forglobalcompanies,over-dependenceonasingle

marketcanconcentratecommercialriskandincrease

theimpactofpolicychangesthatmaybeimposedtolimitgrowthinpayerexpenditureonmedicines.Inthiscontext,ametricofpositiveprogressin2025wouldbetheshareofglobalbrandeddrugsalesfromoutside

theU.S.increasingtomorethan40%,alevelnotseensince2013.

Collectively,these10indicatorsofprogressforthelifesciencessectorrepresentadiverserangeoffactors

thatcurrentlypreventtheindustryfromrealizingitsfullpotential.Achievingtheindicatedlevelsofchangewillreflectmeaningfuladvancementforthesector

—andpositiveoutcomesforotherstakeholderswhorelyonlifesciencesfortheadvancementofhealthandwellnessforall.

2|2025IndicatorsofProgressfortheLifeSciencesSector:Howwillweknowifthesectorisadvancingin2025?

|3

1.Greatertrustinlifesciencescompanies

Publictrustinthepharmaceuticalindustryhasdecreasedoverthelastfewyearstoapointwhereonly20%ofthepublichaspositiveviewsoftheindustryin2024,lower

thanallotherindustriesanddespiteaverysmallincreasefrom20231(Exhibit1).Thislackofpositivereputation

reflectsgeneralperceptionsthatpharmaceutical

manufacturersareprioritizingprofitsoveradvancesinpatientandpublichealththathavebeenamplifiedbyactionssuchasoff-labelmarketing,overcharginggovernmentprograms,andconcealingdata.2

WhiletheCOVID-19pandemicinitiallygavea

positiveboosttothepharmaceuticalindustryafter

vaccinesandtherapeuticswereintroduced3,thiswasreversed,partiallyinfluencedbycriticswhoblamed

pharmaceuticalcompaniesforworkinghand-in-handwithpublichealthauthoritieswhowereenforcingstrictmeasurestocombatthespreadofinfections,includingvaccinemandates,socialdistancingandlock-downs,

thatincreasinglybecamemoreunpopular.Lowtrustinfederal,stateandlocalpublichealthagenciesappeartohavebeenassociatedwithconcernsaboutprivatesectorinfluence,excessiverestrictions,andlowtrustingovernmentoverall.4

Exhibit1:RatingsofU.S.industriesandsectors,2023–24

Farming/AgricultureAccounting Sports Retail Education Airline Movie Television Banking LegalOilandGas

Advertising/Publicrelations

TheFederalGovernmentPharmaceutical

%2023%2024Changepct.pts.

43

31

36

36

35

34

34

35

25

24

21

25

18

59

46424240

37363535

28

27

26

25

20

64

5

3

11

6

2

2

2

2

1

3

3

1

5

2

%Very/Somewhatpositive

Source:

/poll/650318/grocery-restaurant-industry-images-slide.aspx

.

Lowtrustinfederal,stateandlocalpublichealthagenciesappeartohavebeenassociatedwithconcernsaboutprivatesectorinfluence,excessiverestrictions,andlowtrustingovernmentoverall.

Trustinthepharmaceuticalindustrymatters.5Itimpactsthewillingnessofpolicymakersandpolicyinfluencers

toworkwithandsupportindustry,andthewillingnessofhealthcareprovidersandpatientorganizations

topartnerwithindustry.Itcanimpactrecruitment

andretentionoftalent.Itcanimpactpatients’trust

inmedicinesandtheirwillingnesstoparticipatein

clinicaltrials.Anditcandrivevaccinehesitancy,the

abandonmentofprescribedtreatments,andlow

adherenceratesforchronicmedicines.Therefore,an

improvementinthepublictrustisessentialforthe

pharmaceuticalindustry.Thiswillrequirestrategicandsustainedeffortstoenhancethequalityofinformationsharedwiththepublic,toadvancetransparencyaboutindustryresearch,products,andbroaderpublichealthefforts,tolistentothepublicandpatients,andtobuildtrustingrelationshipsandpartnershipswithallrelevantstakeholders,includingclinicians,providers,payers,

patients,policymakersandpolicyinfluencers.

Thepharmaceuticalindustryhasmadeeffortsover

recentyearstocounterthenegativeperceptionsof

theindustryandboostitsreputation,includingthe

advertisingcampaign“GoBoldly,”amulti-yearefforttohighlightthecurrenteraofrevolutionarybiomedical

scienceandshowcasetheindustry’sunsungheroes

whoaredrivingcutting-edgeadvancesinscienceandhighlightingthetremendousopportunitythatexists

totacklethemostcomplexanddevastatinghealth

conditions.6Therearealsohopesthatrecentadvancesinnoveloncologytherapies,effectiveGLP-1obesity

medications,andotherbiotherapeuticinnovations,

suchascellandgenetherapies,willfurthersupporttherebuildingofapositiveindustryimage.

In2025,animprovementinthepublicviewofthe

pharmaceuticalindustrywillbeapositiveindicatorofprogressforthesector,especiallyifthepositiveviewincreasesfrom20%to25%ormore.Thiswouldstill

reflectalowlevelofpublicperceptionandtrust,butameasureableimprovementoverthecourseoftheyear.

INDICATOROFPROGRESS

Improvementinthepositivepublicviewofthepharmaceuticalindustryin2025

to25%from20%in2024

Trustinthepharmaceuticalindustrymatters.Itimpactsthewillingnessofpolicymakersandpolicyinfluencerstoworkwithandsupport

industry,andthewillingnessofhealthcareprovidersandpatientorganizationstopartnerwithindustry.

4|2025IndicatorsofProgressfortheLifeSciencesSector:Howwillweknowifthesectorisadvancingin2025?

|5

2.Reductioninout-of-pocketcostsforpatients

Patientout-of-pocketcostsforprescriptiondrugsareaflashpointintheU.S.healthcaresystemandunderpinmuchofthepoliticaldiscussionaboutdrugpricing.

Aggregateout-of-pocketcostsreached$91Bnin2023,anincreaseof$5Bnovertheprioryear,andlargely

associatedwithretailpharmacydrugs.

Morethan92%ofprescriptionshaveafinalout-of-pocketcostbelow$20,mostlyforgenericdrugsthatcarrylowpatientcosts;however,1%ofprescriptions,or71millionannually,haveassociatedpatientcostsabove$125.

Moreover,1%ofpatientsreachannualout-of-pocket

costsabove$2,000,andamongMedicarebeneficiaries,some3%reachthislevel,largelyduetobenefitdesign.7

During2024(throughOctober31),averagebrand

out-of-pocketcostsrosesharplyandreached$28.22,driveninpartbytheincreasingvolumeofprescriptionsforweight-lossdrugs,whichinsomecasesarenot

coveredbyinsurance(Exhibit2).Thepercentageof

brandprescriptionsfilledbypatientsandcarryingacostofmorethan$125alsoincreasedto4.3%oftotaltransactions.

Whiletheunderlyingdriversofpatientout-of-pocket

costsaremanyandvaried—includinginsurancedesign,pharmacybenefitmanagerpractices,CMSpolicy,

manufacturerpricing—thevisibilityofthesecostsandtheattentiontheydrawparticularlybypolicymakers

meantheycarrydisproportionateimportancetotheoveralllifesciencessector.

Exhibit2:Averagebrandout-of-pocketcostandshareover$125,2018—YTDOct2024

$30

$28

$26

$24

$22

$20

$18

$16

Averagebrand*out-of-pocketcost

5.0%

$28.22

4.5%

$26.01

4.0%

$25.72

$24.33

3.5%

3.0%

2.5%

2.0%

201820192020202120222023YTDOct2024

Shareofbrand*prescriptions

without-of-pocketcosts>$125

4.3%

4.0%

4.0%

3.6%

201820192020202120222023YTDOct2024

AllbrandsAllbrandsexclGLP-1s

Source:IQVIALibraries–Out-of-PocketCostLibrary,Oct2024;IQVIAInstitute,Dec2024.

*includesbrandsandbrandedgenerics.

Thevisibilityofthesecostsandtheattentiontheydrawparticularlyby

policymakersmeantheycarrydisproportionateimportancetotheoveralllifesciencessector.

6|2025IndicatorsofProgressfortheLifeSciencesSector:Howwillweknowifthesectorisadvancingin2025?

Fingerpointingamongstakeholdersastowhois

responsible,andpolicyinterventionsthattargetthesecostsbutcanhavesignificantunintendedconsequences,havebecomecommonplace.Therefore,progressin

reducingthelevelofout-of-pocketcostsandthenumberofAmericanswhofaceunaffordablelevelswilltranslatetoprogressforthelifesciencessectormorebroadly.

Throughout2024,anumberofbipartisanhealth

legislationswerepassedintheU.S.Congress,includinganextensionoftelehealthflexibilitythatoriginated

fromtheCOVID-19pandemic8,andarangeofhealth

legislationsregardingMedicare,poisoncontroland

Alzheimer’sdisease.9Despitebipartisanagreement

abouttheurgencytoreformandensuretransparencyaboutpharmacybenefitsmanagementtolowerdrugpricesandout-of-pocketcostsforpatients,legislationwasnotenacted.ThemomentumforPharmacyBenefit

ManagerPBM-reformwasgrowinginCongressfollowingareportbytheFederalTradeCommissionandseveral

committeehearingsbutCongresswasnotabletomoveforwardwithalegislativeinitiative.10

During2025wecanexpecttoseePBMlegislation

resurfaceinthenewCongress,whilefullimplementationoftheInflationReductionActwillcapcoinsurancefor

Medicarebeneficiariesat$2000.Meaningfulimpact

forpatients—andthelifesciencessector—wouldbe

achievediftheaveragebrandout-of-pocketcostreversestheupwardtrendseensince2021andfallsbelow$25

in2025.Inaddition,iffewerthan3%ofthebrand

prescriptionsfilledcarryout-of-pocketcostsover$125,thiscanbeseenasamarkerofprogressandwillreducethetensionsthatresultfromthecurrentlevelofpatientresponsibilityfordrugcosts.

INDICATORSOFPROGRESS

•AveragebrandOOPcostfallsbelow$25

•ShareofbrandprescriptionswithOOPover$125fallstolessthan3%

Progressinreducingthelevelofout-of-pocketcostsandthenumberof

Americanswhofaceunaffordablelevelswilltranslatetoprogressforthelifesciencessectormorebroadly.

|7

3.Expandedpatientaccesstohealthcareservices

Patientaccesstohealthcareservicesisafundamentalrequirementforahealthsystemtofunction.Increasedaccesstoservicescanpointtomorediagnoses,leadingtoearlierinitiationofpharmacotherapies,offering

treatmentoptionstoundertreatedpopulations,anddrivingappropriateuseofmedicines.Itisalsodirectlylinkedtotheabilityoflifesciencescompaniesto

contributetothepreventionortreatmentofdisease.

Accesstohealthcareserviceswasdisruptedduring

theCOVID-19pandemicandhasnotfullyrecovered,leavingscreening,diagnosis,andtreatmentgaps.7

Therearealsostructuralchallengestopatientaccess,includingtheclosureofnearly2,300pharmaciesintheU.S.sincethebeginningof2024.11Inaddition,useoftelehealthserviceshasdeclinedsincethepeakofthepandemic,andwhileCongresshasextendedmany

MedicaretelehealthflexibilitiesthroughMarch31,2025,intheAmericanReliefAct2025,thereremainslonger-termunpredictabilityinreimbursementfortelehealthproviders.12Therearealsohealthcareworkforce

challengesintheU.S.,wherethemedicalcolleges

projectaphysicianshortageofupto86,000physiciansby2036.13Therearesimilarchallengesgloballywithanestimatedshortageof6.4millionphysiciansin

132countries.14

Proxymeasuresforpatientaccesstohealthcareservicesincludethenumberofretailpharmaciesinoperation,

thenumberofactiveprescribersper100,000population,andgrowthinthenumberofprescriptionsfilledper

capita.Acrossthesemeasures,declininglevelof

availabilityanduseareobservedinthemostrecent2024data(Exhibit3).

Exhibit3:Patientaccesstohealthcareservices

IndexofretailpharmaciesJan2020

toOct2024

100

99

98

97

96

95

94

93

92

91

90

520

518

516

514

512

510

508

506

504

502

1-1-2020

7-1-2020

1-1-2021

7-1-2021

1-1-2022

7-1-2022

1-1-2023

7-1-2023

1-1-2024

7-1-2024

500

Activeprescribersper100kpopulation

>65years

2020202120222023YTDOct2024

10%

5%

0%

-5%

-10%

-15%

Percapitaprescriptiongrowth

2020202120222023YTDOct2024

NBRxTRx

Source:IQVIASupplierRelations,Nov2024.

Increasedaccesstoservicescanpointtomorediagnoses,leadingtoearlierinitiationofpharmacotherapies,offeringtreatmentoptionstoundertreatedpopulations,anddrivingappropriateuseofmedicines.

8|2025IndicatorsofProgressfortheLifeSciencesSector:Howwillweknowifthesectorisadvancingin2025?

Effortstoexpandpatientaccesstohealthcareservices—especiallyinunderservedpopulationsand

communities—havebeenpursuedbymultiplepolicyandbusinessinitiatives.Theexpansionoftelehealthservicesandreimbursementduringthepandemicisonesuchexample—notwithstandingthelong-termuncertaintythatremains.Homecaresolutions,wherehealthcareservicesaredeliveredinthepatient’s

home—turningthehomeintothe“hospitalofthe

future”—arealsobeingpurusedbyhealthsystems.15Theincorporationofdigitaltoolstoenableremote

monitoring,supportpatientengagementanddeliverdigitaltherapeuticsandcarealsoprovideexpandedopportunitiesforhealthcareservices.16

Improvementsinpatientaccesstohealthcareservicesin2025willbeapositiveindicatorforlifesciences

companies.Proxymeasurescanbeusedtoreflect

progressduringthecourseoftheyear.Stabilizationinthenumberofretailpharmaciesatthelevelrecordedattheendof2023wouldmarkprogress,especially

totheextentthatclosuresofpharmaciesinover-

saturatedurbanareasareoffsetbynewpharmacies

openingin“pharmacydeserts”orcommunitiescurrentlyunderserved.Anincreaseinthenumberofactive

primarycarephysiciansrelativetothepopulationovertheageof65wouldalsobeapositivemeasureifthis

returnedtothe2023levelof518family/internalmedicineprescribersper100,000populationover65years.

Finally,anotherpositivemeasurewouldbegrowthin

newbrandprescription(NBRx)startsrisingfrom1.5%fortheyear-to-dateOctober2024tomorethan4%in

2025,asseeninthepriorthreeyears,andsignallingtheinitiationoftreatmentformorepatients.

Stabilizationinthenumberofretail

pharmaciesatthelevelrecordedattheendof2023wouldmarkprogress.

INDICATORSOFPROGRESS

•Numberoftotalactivepharmaciesstabilizesatthelevelseenattheendof2023

•Numberoffamily/internalmedicineactiveprescribersreaches518per100,000populationover65years,anincreaseof2%overthenumberinOctober2024andareturntothelevelof2023

•GrowthinNBRxofmorethan4%in2025,upfrom1.5%inYTDOctober2024

|9

4.Progressonthe“MakeAmericaHealthyAgain”agenda

ThenewTrumpadministrationandthenominated

secretaryfortheDepartmentofHealthandHuman

Services,RobertF.KennedyJr.,havepromiseda

sweepingefforttooverhaulU.S.healthpoliciesunderthe“MakeAmericaHealthyAgain”(MAHA)slogan.

Keyelementsintheambitiousplansincludeanew

strategyforcurbingtheriseinchronicdiseasesin

America,firstandforemostamongchildren,but

amongAmericansofallagesaswell,bansand/or

restrictionsontheuseofchemicalsinagricultureand

food,andareformoftheleadinghealthagenciesin

theU.S.,includingtheFDA,NIHandCDCaimingto

cleanupallegedcorruptionintheinteractionbetweengovernmentofficialsandindustrylobbyists.Inaddition,effortstoreduceover-regulationacrossallpartsof

theeconomycouldalsohaveanimpactonregulatory

reviewsandguidancethataffectlifesciencescompanies,includingnewdrugapprovals,safetymonitoring,and

long-termfollow-upstudies.

RobertF.KennedyJr.—whoissubjecttoSenate

confirmation—hasmadeacallforarobusteffortto

combattheriseinchronicdiseasesintheU.S.,which

reflectsthebroadrecognitionoftheseriousnature

ofthisissue,asevidencedbyanabundanceofdata.17Theadministration’semphasisisexpectedtobeon

understandingandaddressingtherootcausesof

chronicdiseases,includinglifestyle,foodandnutrition,andtheenvironment.

PlansbytheDepartmentofGovernmentEfficiency

(DOGE)mayalsofallundertheMAGAagenda,in

particularthosethatincludereducingregulatory

barrierstolower-cost,higher-qualityhealthinsuranceandmedicalcare.Somehavesuggestedthiswould

involvemajorreformsoftheroleandoperationof

theFoodandDrugAdministration18andcouldlead

toareductionintheelapsedtimefornewlypatented

medicinestobelaunchedintheU.S.,whichcurrently

standsatamedianof13.8yearsfornewdrugslaunchedthroughSeptember30,2024,thelongestperiodsince2017(Exhibit4).

Exhibit4:TimefromfirstpatentfilingtoU.S.launchfornovelactivesubstances,2014-2024

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

20142015201620172018201920202021202220232024*

.0-5years6-10years.11-15years16-20years.20+yearsMedian

20

10

0

Source:IQVIAInstituteNASDatabase,December2024.

*YTDSept30,2024.

10|2025IndicatorsofProgressfort